Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | TPH1 | P17752 | 1/20 | 0.49 |
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155049 | 1.00 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL16360425 | 0.89 | CSK (0.43) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL9780166 | 0.89 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL12028154 | 0.86 | SLC7A5 (0.53) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2778660 | 0.85 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL1104653 | 0.85 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31255228 | 0.85 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15081041 | 0.84 | ALDH1A1 (0.46) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL6774191 | 0.84 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL6774195 | 0.84 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| EP-3572091-B1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20080113412-A1 | Blood plasma protein conjugated to apolipoproteins for use in treatment of metabolic disorders | AMBRX, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080107680-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080107680-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080102124-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102124-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102125-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102125-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| WO-2006069220-A9 | MODIFIED HUMAN GROWTH HORMONE | AMBRX INC (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | SLC7A5 264/4885PTGS1 4544/4885ALPI 2388/4885 |
| US-20080102124-A1 | Modified Human Growth Hormone | GHRHR, GHITM, GHSR | SLC7A5 2983/4885PTGS1 3265/4885ALPI 1783/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | SLC7A5 2905/4885PTGS1 2511/4885ALPI 2703/4885 |
| US-20080102125-A1 | Modified Human Growth Hormone | GHRHR, GHITM, GHSR | SLC7A5 2983/4885PTGS1 3265/4885ALPI 1783/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | SLC7A5 2188/4885PTGS1 2770/4885ALPI 3027/4885 |
| US-20080113412-A1 | Blood plasma protein conjugated to apolipoproteins for use in treatment of metabolic disorders | APOB, FABP1, HDLBP | SLC7A5 1129/4885PTGS1 4480/4885ALPI 611/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | SLC7A5 221/4885PTGS1 4492/4885ALPI 1996/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | SLC7A5 2122/4885PTGS1 644/4885ALPI 3130/4885 |
| US-20080107680-A1 | Modified Human Growth Hormone | GHRHR, GHITM, GHSR | SLC7A5 2983/4885PTGS1 3265/4885ALPI 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.